Literature DB >> 21547158

Integrin targeted therapeutics.

Melissa Millard1, Srinivas Odde, Nouri Neamati.   

Abstract

Integrins are heterodimeric, transmembrane receptors that function as mechanosensors, adhesion molecules and signal transduction platforms in a multitude of biological processes. As such, integrins are central to the etiology and pathology of many disease states. Therefore, pharmacological inhibition of integrins is of great interest for the treatment and prevention of disease. In the last two decades several integrin-targeted drugs have made their way into clinical use, many others are in clinical trials and still more are showing promise as they advance through preclinical development. Herein, this review examines and evaluates the various drugs and compounds targeting integrins and the disease states in which they are implicated.

Keywords:  Crohn's Disease; Integrin-targeted therapeutics; Multiple Sclerosis; abciximab; abegrin; acute coronary syndromes; age related macular degeneration; angiogenesis; cancer; cilengitide; eptifibatide; integrin-targeted peptides; integrin-targeted small molecules; integrin-targeted therapeutic antibodies; natalizumab; osteoporosis; tirofiban

Year:  2011        PMID: 21547158      PMCID: PMC3086618          DOI: 10.7150/thno/v01p0154

Source DB:  PubMed          Journal:  Theranostics        ISSN: 1838-7640            Impact factor:   11.556


  144 in total

1.  Evidence-based emergency medicine/systematic review abstract. Role of abciximab in the management of acute ischemic stroke.

Authors:  Latha G Stead; Lekshmi Vaidyanathan
Journal:  Ann Emerg Med       Date:  2008-08-22       Impact factor: 5.721

2.  The very late antigen family of heterodimers is part of a superfamily of molecules involved in adhesion and embryogenesis.

Authors:  Y Takada; J L Strominger; M E Hemler
Journal:  Proc Natl Acad Sci U S A       Date:  1987-05       Impact factor: 11.205

3.  Identification of a murine Peyer's patch--specific lymphocyte homing receptor as an integrin molecule with an alpha chain homologous to human VLA-4 alpha.

Authors:  B Holzmann; B W McIntyre; I L Weissman
Journal:  Cell       Date:  1989-01-13       Impact factor: 41.582

4.  Binding of osteopontin to the osteoclast integrin alpha v beta 3.

Authors:  A Miyauchi; J Alvarez; E M Greenfield; A Teti; M Grano; S Colucci; A Zambonin-Zallone; F P Ross; S L Teitelbaum; D Cheresh
Journal:  Osteoporos Int       Date:  1993       Impact factor: 4.507

5.  gamma and alpha chains of human fibrinogen possess sites reactive with human platelet receptors.

Authors:  J Hawiger; S Timmons; M Kloczewiak; D D Strong; R F Doolittle
Journal:  Proc Natl Acad Sci U S A       Date:  1982-03       Impact factor: 11.205

6.  Platelet glycoprotein IIb-IIIa protein antagonists from snake venoms: evidence for a family of platelet-aggregation inhibitors.

Authors:  M S Dennis; W J Henzel; R M Pitti; M T Lipari; M A Napier; T A Deisher; S Bunting; R A Lazarus
Journal:  Proc Natl Acad Sci U S A       Date:  1990-04       Impact factor: 11.205

7.  Inhibition of osteoclastic bone resorption in vivo by echistatin, an "arginyl-glycyl-aspartyl" (RGD)-containing protein.

Authors:  J E Fisher; M P Caulfield; M Sato; H A Quartuccio; R J Gould; V M Garsky; G A Rodan; M Rosenblatt
Journal:  Endocrinology       Date:  1993-03       Impact factor: 4.736

8.  Meta-analysis of clinical efficacy and bleeding risk with intravenous glycoprotein IIb/IIIa antagonists for percutaneous coronary intervention.

Authors:  Marino Labinaz; Chuong Ho; Srabani Banerjee; Janet Martin; Stella Chen; Shaila Mensinkai
Journal:  Can J Cardiol       Date:  2007-10       Impact factor: 5.223

9.  A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin alpha(v)beta(3), + or - dacarbazine in patients with stage IV metastatic melanoma.

Authors:  Peter Hersey; Jeffrey Sosman; Steven O'Day; Jon Richards; Agop Bedikian; Rene Gonzalez; William Sharfman; Robert Weber; Theodore Logan; Manuela Buzoianu; Luz Hammershaimb; John M Kirkwood
Journal:  Cancer       Date:  2010-03-15       Impact factor: 6.860

10.  An antagonist of integrin alpha v beta 3 prevents maturation of blood vessels during embryonic neovascularization.

Authors:  C J Drake; D A Cheresh; C D Little
Journal:  J Cell Sci       Date:  1995-07       Impact factor: 5.285

View more
  87 in total

Review 1.  Blood Brothers: Hemodynamics and Cell-Matrix Interactions in Endothelial Function.

Authors:  Arif Yurdagul; A Wayne Orr
Journal:  Antioxid Redox Signal       Date:  2016-02-19       Impact factor: 8.401

2.  Radiolabeled Angiogenesis-Targeting Croconaine Nanoparticles for Trimodality Imaging Guided Photothermal Therapy of Glioma.

Authors:  Longguang Tang; Xiaoli Sun; Nian Liu; Zijian Zhou; Fei Yu; Xianzhong Zhang; Xiaolian Sun; Xiaoyuan Chen
Journal:  ACS Appl Nano Mater       Date:  2018-03-20

Review 3.  Focal adhesion complex proteins in epidermis and squamous cell carcinoma.

Authors:  Elizabeth K Duperret; Todd W Ridky
Journal:  Cell Cycle       Date:  2013-09-12       Impact factor: 4.534

Review 4.  Reconstruction of integrin activation.

Authors:  Feng Ye; Chungho Kim; Mark H Ginsberg
Journal:  Blood       Date:  2011-09-14       Impact factor: 22.113

Review 5.  Understanding the bone marrow microenvironment in hematologic malignancies: A focus on chemokine, integrin, and extracellular vesicle signaling.

Authors:  Edward Allan Racela Sison; Peter Kurre; Yong-Mi Kim
Journal:  Pediatr Hematol Oncol       Date:  2017-12-06       Impact factor: 1.969

6.  Effects of VLA-1 Blockade on Experimental Inflammation in Mice.

Authors:  Ryuichi Totsuka; Takaaki Kondo; Shigeki Matsubara; Midori Hirai; Yoichi Kurebayashi
Journal:  Kobe J Med Sci       Date:  2016-07-05

7.  Construction, expression, and purification of recombinant αVβ5 integrin.

Authors:  Lawrence J Tartaglia; Antonette Bennett; Andrew G Woodhouse; Fikret Aydemir; Nicholas Muzyczka; Mavis Agbandje-McKenna
Journal:  Protein Expr Purif       Date:  2013-04-12       Impact factor: 1.650

Review 8.  Integrin αIIbβ3: from discovery to efficacious therapeutic target.

Authors:  Kamila Bledzka; Susan S Smyth; Edward F Plow
Journal:  Circ Res       Date:  2013-04-12       Impact factor: 17.367

9.  RGD-modified apoferritin nanoparticles for efficient drug delivery to tumors.

Authors:  Zipeng Zhen; Wei Tang; Hongmin Chen; Xin Lin; Trever Todd; Geoffrey Wang; Taku Cowger; Xiaoyuan Chen; Jin Xie
Journal:  ACS Nano       Date:  2013-06-04       Impact factor: 15.881

Review 10.  Enhancing integrin function by VEGF/neuropilin signaling: implications for tumor biology.

Authors:  Hira Lal Goel; Arthur M Mercurio
Journal:  Cell Adh Migr       Date:  2012-10-17       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.